Woolsey Secures U.S. Patent for Bravyl in Treating ALS
10 Jan 2025 //
PR NEWSWIRE
Woolsey Pharma Reveals BRAVYL® Reduces Toxic TDP-43 Spread in ALS
09 Dec 2024 //
PR NEWSWIRE
Woolsey Pharma Completes ALS Study High-Dose Cohort Recruitment
12 Nov 2024 //
PR NEWSWIRE
Woolsey Pharmaceuticals Granted Patents To Strengthen IP Position
21 Oct 2024 //
PR NEWSWIRE
Woolsey Treats First ALS Patient With Higher-Dose BRAVYL In REAL Study
08 Jul 2024 //
PR NEWSWIRE
Woolsey Pharmaceuticals Signs License Agreement With Asahi Kasei Pharma
25 Nov 2019 //
BUSINESS WIRE